Display options
Cite
Ye ZH, Gao L, Wen DY, et al. Diagnostic and prognostic roles of IRAK1 in hepatocellular carcinoma tissues: an analysis of immunohistochemistry and RNA-sequencing data from the cancer genome atlas. Onco Targets Ther. 2017;10:1711-1723doi: 10.2147/OTT.S132120.
Ye, Z. H., Gao, L., Wen, D. Y., He, Y., Pang, Y. Y., & Chen, G. (2017). Diagnostic and prognostic roles of IRAK1 in hepatocellular carcinoma tissues: an analysis of immunohistochemistry and RNA-sequencing data from the cancer genome atlas. OncoTargets and therapy, 101711-1723. https://doi.org/10.2147/OTT.S132120
Ye, Zhi-Hua, et al. "Diagnostic and prognostic roles of IRAK1 in hepatocellular carcinoma tissues: an analysis of immunohistochemistry and RNA-sequencing data from the cancer genome atlas." OncoTargets and therapy vol. 10 (2017): 1711-1723. doi: https://doi.org/10.2147/OTT.S132120
Ye ZH, Gao L, Wen DY, He Y, Pang YY, Chen G. Diagnostic and prognostic roles of IRAK1 in hepatocellular carcinoma tissues: an analysis of immunohistochemistry and RNA-sequencing data from the cancer genome atlas. Onco Targets Ther. 2017 Mar 21;10:1711-1723. doi: 10.2147/OTT.S132120. eCollection 2017. PMID: 28356759; PMCID: PMC5367901.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2017 Mar 21;10:1711-1723. doi: 10.2147/OTT.S132120. eCollection 2017.

Diagnostic and prognostic roles of IRAK1 in hepatocellular carcinoma tissues: an analysis of immunohistochemistry and RNA-sequencing data from the cancer genome atlas.

OncoTargets and therapy

Zhi-Hua Ye, Li Gao, Dong-Yue Wen, Yun He, Yu-Yan Pang, Gang Chen

Affiliations

  1. Department of Pathology.
  2. Department of Ultrasonography, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China.

PMID: 28356759 PMCID: PMC5367901 DOI: 10.2147/OTT.S132120

Abstract

BACKGROUND: IRAK1 has been repoted to play an essential role in the development of multiple cancers. However, the clinical significance of IRAK1 in hepatocellular carcinoma (HCC) and the underlying molecular mechanism remain unclear. Therefore, we aimed to investigate the role of IRAK1 in the pathogenesis of HCC in this study.

MATERIALS AND METHODS: HCC tissues and para-carcinoma tissues were collected for immunohistochemistry (IHC) analysis to evaluate IRAK1 expression. Data of IRAK1 expression were downloaded from the cancer genome atlas (TCGA) for analyzing the clinical significance of IRAK1. Receiver operating characteristic (ROC) curve and survival analyses were carried out to assess the diagnostic and prognostic significance of IRAK1 in IHC and TCGA data. Additionally, we investigated the alteration of

RESULTS: Analysis of both IHC and TCGA data revealed a significant upregulation of IRAK1 in HCC tissues. The IHC analysis revealed there was an increasing trend in IRAK1 expression among normal liver tissues, liver cirrhosis tissues, para-carcinoma tissues and HCC tissues. The ROC curves for IHC and TCGA data demonstrated that IRAK1 exhibited a significant diagnostic value for HCC. Moreover, IRAK1 expression was observed to be associated with tumor size, metastasis and T-stage. The survival analysis indicated that the upregulation of IRAK1 predicted a worse overall survival of HCC. Additionally, data from cBioPortal confirmed that 29% of HCC tissues possessed an alteration of the

CONCLUSION: IRAK1 may act as an oncogene in the development of HCC with its overexpression in HCC. Moreover, IRAK1 might serve as a promising diagnostic and therapeutic target for HCC.

Keywords: IRAK1; RNA-seq; diagnosis; hepatocellular carcinoma; immunohistochemistry; prognosis

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

References

  1. Nat Cell Biol. 2014 Dec;16(12 ):1238-48 - PubMed
  2. J Clin Invest. 2001 Jan;107(1):13-9 - PubMed
  3. Cancer Cell Int. 2016 Sep 29;16:76 - PubMed
  4. World J Gastroenterol. 2016 Sep 14;22(34):7645-59 - PubMed
  5. Nat Commun. 2015 Oct 27;6:8746 - PubMed
  6. Clin Cancer Res. 2010 Jan 1;16(1):34-44 - PubMed
  7. Biochem Pharmacol. 2010 Dec 15;80(12):1981-91 - PubMed
  8. J Hepatocell Carcinoma. 2016 Oct 05;3:41-53 - PubMed
  9. Cancer Cell. 2013 Jul 8;24(1):90-104 - PubMed
  10. Immunity. 1997 Dec;7(6):837-47 - PubMed
  11. Mol Cell. 2003 Feb;11(2):293-302 - PubMed
  12. Onco Targets Ther. 2016 Mar 21;9:1721-34 - PubMed
  13. CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32 - PubMed
  14. Sci Signal. 2013 Apr 02;6(269):pl1 - PubMed
  15. Oncogene. 2008 Sep 18;27(42):5643-7 - PubMed
  16. Science. 1996 Feb 23;271(5252):1128-31 - PubMed
  17. Cancer Res. 2010 Feb 15;70(4):1486-95 - PubMed
  18. Cell Signal. 2001 Feb;13(2):85-94 - PubMed
  19. Int J Clin Exp Pathol. 2014 Oct 15;7(11):8096-104 - PubMed
  20. J Exp Clin Cancer Res. 2016 Sep 13;35(1):140 - PubMed
  21. Cancer Discov. 2012 May;2(5):401-4 - PubMed
  22. Nat Rev Immunol. 2013 Jun;13(6):453-60 - PubMed
  23. Gastroenterology. 2017 Mar;152(4):812-820.e5 - PubMed
  24. Cancer Res. 2012 Dec 1;72(23):6209-16 - PubMed
  25. Nat Rev Cancer. 2009 Jan;9(1):57-63 - PubMed
  26. Clin Cancer Res. 2011 Jul 1;17(13):4277-84 - PubMed
  27. Haematologica. 2015 Nov;100(11):1460-8 - PubMed
  28. CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30 - PubMed
  29. J Clin Invest. 2015 Mar 2;125(3):1081-97 - PubMed
  30. Oncologist. 2010;15 Suppl 4:5-13 - PubMed
  31. Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):E4762-8 - PubMed

Publication Types